FDA 483 - Sinopep-Allsino Biopharmaceutical Co., Ltd. - September 20, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Sinopep-Allsino Biopharmaceutical Co., Ltd in Lianyungang, China, revealed critical deficiencies in manufacturing practices. Observations included inadequate cleaning of major production equipment leading to API residue and foreign object contamination, as well as poor facility maintenance with water leaks in storage and laboratory areas. Additionally, the firm failed to implement effective pest control measures, resulting in insects and cobwebs in raw material storage.
- Inspection Date
- September 20, 2024
- Product Type
- Drugs
ID · fe7d76a3-ef64-476f-a140-fa69137d953e